Evaluation of crystal violet decolorization assay for minimal inhibitory concentration detection of primary antituberculosis drugs against Mycobacterium tuberculosis isolates.
In this study we evaluated the crystal violet decolorization assay (CVDA) for detection of minimum inhibitory concentration (MIC) of antituberculosis drugs. 53 isolates were tested in this study and 13 of them were multidrug resistant (MDR) isolates. The antibiotics concentrations were 2-0.06 mg/L for isoniazid (INH) and rifampicin (RIF) and were 16-0.25 mg/L for streptomycin (STM) and ethambutol (EMB). Crystal violet (CV-25 mg/L) was added into the microwells on the seventh day of incubation and incubation was continued until decolorization. Decolorization of CV was the predictor of bacterial growth. Overall agreements for four drugs were detected as 98.1%, and the average time was detected as 9.5 ± 0.89 day after inoculation. One isolate for INH and two isolates for STM were determined resistant in the reference method, but susceptible by the CVDA. One isolate was susceptible to EMB by the reference method, but resistant by the CVDA. All results were concordant for RIF. This study shows that CVDA is a rapid, reliable and suitable for determination of MIC values of Mycobacterium tuberculosis. And it can be used easily especially in countries with limited-sources.
Ondokuz Mayis University, Ondokuz Mayis University, Medical School, Department of Medical Microbiology, Samsun , Turkey, Ondokuz Mayis University Medical School, Department of Medical Microbiology, Samsun, Turkey.
Ahmet Yilmaz
AY
Coban
Ondokuz Mayis University, Ondokuz Mayis University, Medical School, Department of Medical Microbiology, Samsun , Turkey, Ondokuz Mayis University Medical School, Department of Medical Microbiology, Samsun, Turkey.
Ahmet Ugur
AU
Akbal
Istanbul University, Istanbul University, Istanbul Medical School, Department of Medical Microbiology, Istanbul , Turkey, Istanbul University Istanbul Medical School, Department of Medical Microbiology, Istanbul, Turkey.
Meltem
M
Uzun
Ondokuz Mayis University, Ondokuz Mayis University, Medical School, Department of Medical Microbiology, Samsun , Turkey, Ondokuz Mayis University Medical School, Department of Medical Microbiology, Samsun, Turkey.
Yeliz Tanriverdi
YT
Cayci
Ondokuz Mayis University, Ondokuz Mayis University, Medical School, Department of Medical Microbiology, Samsun , Turkey, Ondokuz Mayis University Medical School, Department of Medical Microbiology, Samsun, Turkey.
Asuman
A
Birinci
Ondokuz Mayis University, Ondokuz Mayis University, Medical School, Department of Medical Microbiology, Samsun , Turkey, Ondokuz Mayis University Medical School, Department of Medical Microbiology, Samsun, Turkey.
Belma
B
Durupinar
D000995:Antitubercular Agents / Q000008:administration & dosage / Q000494:pharmacology*; D001681:Biological Assay; D024901:Drug Resistance, Multiple, Bacterial / Q000187:drug effects; D004977:Ethambutol / Q000008:administration & dosage / Q000494:pharmacology; D005840:Gentian Violet / Q000737:chemistry; D006801:Humans; D007202:Indicators and Reagents / Q000737:chemistry; D007538:Isoniazid / Q000008:administration & dosage / Q000494:pharmacology; D008826:Microbial Sensitivity Tests / Q000379:methods; D009169:Mycobacterium tuberculosis / Q000187:drug effects* / Q000254:growth & development; D012293:Rifampin / Q000008:administration & dosage / Q000494:pharmacology; D013307:Streptomycin / Q000008:administration & dosage / Q000494:pharmacology; D018088:Tuberculosis, Multidrug-Resistant / Q000382:microbiology
D000995:Antitubercular Agents; D007202:Indicators and Reagents; D004977:Ethambutol; D005840:Gentian Violet; D007538:Isoniazid; D012293:Rifampin; D013307:Streptomycin